Clinical trials
Recruiting Lung Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
836 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 6 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 9 |
| 2018 | 21 |
| 2019 | 18 |
| 2020 | 23 |
| 2021 | 36 |
| 2022 | 73 |
| 2023 | 120 |
| 2024 | 150 |
| 2025 | 198 |
| 2026 | 145 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 836 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 20 |
| National Cancer Institute (NCI) | 15 |
| Massachusetts General Hospital | 12 |
| Second Affiliated Hospital of Guangzhou Medical University | 12 |
| Shanghai Chest Hospital | 11 |
| Mayo Clinic | 10 |
| Sun Yat-sen University | 9 |
| Assistance Publique - Hôpitaux de Paris | 8 |
| AstraZeneca | 8 |
| Shanghai Pulmonary Hospital, Shanghai, China | 8 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 836 |
| Carcinoma, Non-Small-Cell Lung | 246 |
| Breast Neoplasms | 119 |
| Neoplasms | 84 |
| Colorectal Neoplasms | 77 |
| Pancreatic Neoplasms | 73 |
| Stomach Neoplasms | 57 |
| Ovarian Neoplasms | 55 |
| Prostatic Neoplasms | 51 |
| Melanoma | 48 |
Trials
Showing 1 to 25 of 836. Each trial links to its page on Pharma Observatory.
736 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.